azelastine has been researched along with Asthma in 74 studies
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis." | 9.51 | A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial. ( Alyasin, S; Babaeian, M; Esmaeilzadeh, H; Far, NM; Hadipour, M; Nabavizadeh, SH, 2022) |
| "Seventeen patients (mean age 31 years, 14 m/3 f) with asthma and proven EAR and LAR received an oral dose of 4 mg azelastine twice daily, or 10mg montelukast once daily, or both for 1 week, in a double-blind, double-dummy, cross-over fashion." | 9.13 | Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma. ( Grönke, L; Janicki, S; Jörres, RA; Magnussen, H; Maus, J; Richter, K, 2008) |
| "The study was designed to evaluate the efficacy and safety of azelastine, a novel antiallergy compound, in patients with asthma who required maintenance therapy." | 9.08 | An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. ( , 1996) |
| "To assess the effects of azelastine in patients with cough-variant asthma, we measured the cough threshold for capsaicin (the concentration required to elicit more than five coughs) in 16 patients with cough-variant asthma before and after 4 weeks of treatment with azelastine (2 mg; b." | 9.08 | Cough threshold for capsaicin increases by azelastine in patients with cough-variant asthma. ( Ito, N; Kagaya, M; Kashima, M; Miura, M; Sano, M; Sasaki, M; Shindo, T; Shioya, T, 1996) |
| "To investigate the efficacy of azelastine hydrochloride (azelastine, CAS 79307-93-0, Azeptin) in suppressing cough, 22 bronchial asthma patients complaining mainly of cough were given the drug for four weeks." | 9.08 | Antitussive effect of azelastine hydrochloride in patients with bronchial asthma. ( Ito, N; Kagaya, M; Kimura, K; Miura, M; Miura, S; Sano, M; Shindo, T; Shioya, T; Watanabe, A, 1998) |
| "The aim of this double-blind, multicenter trial was to determine the duration of bronchodilating activity of a single 4-mg dose of azelastine in chronic asthmatics." | 9.08 | Duration of action of a single dose of azelastine in patients with chronic asthma. ( Chervinsky, P; Freitag, JJ; Grossman, J, 1995) |
| "Azelastine is an oral antiallergic compound but there is no direct evidence of its anti-inflammatory actions in bronchial asthma." | 9.08 | The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. ( Hoshino, M; Nakamura, Y, 1997) |
| "The objective of this double-blind trial was to evaluate the corticosteroid-sparing effect of azelastine in patients with chronic bronchial asthma." | 9.08 | Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. ( Bell, TD; Bronsky, EA; Busse, WW; Chu, TJ; D'Eletto, TA; Dam, A; Dockhorn, RJ; Grossman, J; Hemsworth, GR; Mansfield, LE; Middleton, E; Perhach, JL; Storms, W; Weiler, JM, 1996) |
| "The study was carried out to investigate the effect of azelastine on the Substance P (SP) concentration in bronchoalveolar (BAL) and nasal (NAL) lavage obtained from atopic grass pollen asthmatics and non-atopic healthy subjects." | 9.07 | Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. ( Baumgarten, C; Furkert, J; Kunkel, G; Laake, E; Müller, S; Nieber, K; Rathsack, R, 1993) |
| "Azelastine is a new oral antiasthma agent with bronchodilating and antiallergic properties." | 9.06 | Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time. ( Bucholtz, GA; Kemp, JP; Koepke, JW; Repsher, LH; Spector, SL; Storms, WW; Tinkelman, DG; Van As, A, 1990) |
| "4 mg of azelastine administered orally on immediate allergen-induced airflow obstruction was studied in 20 young patients with asthma." | 9.06 | The effect of single and multiple dose therapy with azelastine on the immediate asthmatic response to allergen provocation testing. ( Davies, RJ; Gould, CA; Ollier, S, 1986) |
| "Efficacy and tolerance of azelastine (A 5610; CAS 58581-89-8), a new antiallergic compound with a unique structure, were investigated over up to one year of treatment in 225 male and female out-patients (age mean +/- s = 48 +/- 13 years) suffering from chronified intrinsic asthma." | 9.06 | Long-term multicentric study with azelastine in patients with intrinsic asthma. ( Nowak, H; Ulbrich, E, 1990) |
| "4 mg azelastine administered orally on airway responsiveness, skin prick testing, daily peak expiratory flow rates and symptoms of asthma was compared with placebo in a 7 week double-blind, parallel group study of 24 patients with extrinsic asthma." | 9.06 | A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. ( Aurich, R; Davies, RJ; Gould, CA; Ollier, S, 1988) |
| "The effects of the new anti-allergic drug, azelastine, on allergen- and exercise-induced asthma were studied." | 9.05 | Effects of azelastine on allergen- and exercise-induced asthma. ( Fukuda, T; Makino, S; Motojima, S; Ohashi, Y; Otsuka, T, 1985) |
| "Because the older antihistamines possessed relatively weak antihistaminic action, as well as sedative and anticholinergic effects, they could not be administered in doses high enough to confer relief to atopic patients with asthma." | 8.78 | Antihistamines in the treatment of clinical asthma. ( Rafferty, P, 1990) |
| "Azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-p hthalazinone hydrochloride), a novel long-acting antiasthmatic/antiallergic drug has been demonstrated to be effective in the treatment both of asthma and of allergic rhinitis." | 8.78 | Azelastine: a multifaceted drug for asthma therapy. ( Achterrath-Tuckermann, U; Minker, E; Paegelow, I; Schmidt, J; Szelenyi, I; Werner, H, 1991) |
| "Our results suggest that antihistamine agents may be effective against alcohol-induced asthma by both blocking H1 receptors and inhibiting histamine release." | 7.70 | Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma. ( Asai, S; Kohno, S; Matsuse, H; Mitsuta, K; Obase, Y; Shimoda, T; Takao, A, 1999) |
| "A prospective study was designed in asthmatic children treated with azelastine hydrochloride." | 7.69 | Urinary N-methylhistamine in asthmatic children receiving azelastine hydrochloride. ( Iwashita, M; Kamuro, K; Kumamoto, T; Miyata, K; Shimago, A; Takei, S, 1997) |
| "The influence of aerosolized azelastine on acute lung anaphylaxis in actively sensitized guinea pigs (experimental asthma model) was studied." | 7.67 | Inhibition of acute lung anaphylaxis by aerosolized azelastine in guinea pigs sensitized by three different procedures. ( Chand, N; Diamantis, W; Nolan, K; Sofia, RD, 1987) |
| "This study was designed to clarify whether azelastine, an antiasthmatic drug, could favorably alter bronchial responsiveness in patients with bronchial asthma." | 7.67 | Effect of azelastine, an antiasthmatic drug, on bronchial responsiveness in patients with bronchial asthma. ( Iwata, M; Satake, T; Sugiyama, S; Taki, F; Tano, M, 1989) |
| " Despite azelastine and desmethyl azelastine blood levels that were proportionate to the dosage range, the bronchodilator effect as measured by FEV1 and forced expiratory flow rate between 25% and 75% of FVC was proportionately greater with 4 mg of azelastine during the 8-hour study period than the anticipated bronchodilator response with the 8 and 16 mg doses." | 6.66 | Pharmacodynamic evaluation of azelastine in subjects with asthma. ( Katz, RM; Perhach, JL; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1987) |
| "Azelastine did not inhibit the effect of inhaled LTC4; the geometric mean PD20FEV1 LTC4 (nmol) after a single dose and 14 days' treatment was 0." | 6.66 | Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma. ( Albazzaz, MK; Patel, KR, 1988) |
| "In 12 patients with bronchial asthma we performed histamine bronchial challenges before and four hours after ingestion of placebo, 2." | 6.66 | The inhibitory effect of azelastine and ketotifen on histamine-induced bronchoconstriction in asthmatic patients. ( Magnussen, H, 1987) |
| "Theophylline was stopped 24 hours and other bronchodilators at least 8 hours before the study day." | 6.66 | A dose-response study of the bronchodilator action of azelastine in asthma. ( Bucholtz, GA; Kemp, JP; Meltzer, EO; Middleton, E; Newton, JJ; Orgel, HA; Perhach, JL; Spector, SL; Welch, MJ, 1987) |
| "Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis." | 5.51 | A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial. ( Alyasin, S; Babaeian, M; Esmaeilzadeh, H; Far, NM; Hadipour, M; Nabavizadeh, SH, 2022) |
| " Results demonstrate improved activity of antihistamines by 2 phytochemicals, suggesting dosing strategies for animal trials of ASX- or GB-augmented formulations for seasonal allergic rhinitis and asthma." | 5.38 | In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012) |
| "Azelastine is an oral antiallergic drug." | 5.30 | [The effect of azelastine on bronchial mucosa in bronchial asthma--suppression of cytokine mRNA]. ( Shimojo, J, 1998) |
| "Seventeen patients (mean age 31 years, 14 m/3 f) with asthma and proven EAR and LAR received an oral dose of 4 mg azelastine twice daily, or 10mg montelukast once daily, or both for 1 week, in a double-blind, double-dummy, cross-over fashion." | 5.13 | Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma. ( Grönke, L; Janicki, S; Jörres, RA; Magnussen, H; Maus, J; Richter, K, 2008) |
| "The aim of this double-blind, multicenter trial was to determine the duration of bronchodilating activity of a single 4-mg dose of azelastine in chronic asthmatics." | 5.08 | Duration of action of a single dose of azelastine in patients with chronic asthma. ( Chervinsky, P; Freitag, JJ; Grossman, J, 1995) |
| "The objective of this double-blind trial was to evaluate the corticosteroid-sparing effect of azelastine in patients with chronic bronchial asthma." | 5.08 | Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. ( Bell, TD; Bronsky, EA; Busse, WW; Chu, TJ; D'Eletto, TA; Dam, A; Dockhorn, RJ; Grossman, J; Hemsworth, GR; Mansfield, LE; Middleton, E; Perhach, JL; Storms, W; Weiler, JM, 1996) |
| "The study was designed to evaluate the efficacy and safety of azelastine, a novel antiallergy compound, in patients with asthma who required maintenance therapy." | 5.08 | An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. ( , 1996) |
| "To assess the effects of azelastine in patients with cough-variant asthma, we measured the cough threshold for capsaicin (the concentration required to elicit more than five coughs) in 16 patients with cough-variant asthma before and after 4 weeks of treatment with azelastine (2 mg; b." | 5.08 | Cough threshold for capsaicin increases by azelastine in patients with cough-variant asthma. ( Ito, N; Kagaya, M; Kashima, M; Miura, M; Sano, M; Sasaki, M; Shindo, T; Shioya, T, 1996) |
| "To investigate the efficacy of azelastine hydrochloride (azelastine, CAS 79307-93-0, Azeptin) in suppressing cough, 22 bronchial asthma patients complaining mainly of cough were given the drug for four weeks." | 5.08 | Antitussive effect of azelastine hydrochloride in patients with bronchial asthma. ( Ito, N; Kagaya, M; Kimura, K; Miura, M; Miura, S; Sano, M; Shindo, T; Shioya, T; Watanabe, A, 1998) |
| "Azelastine is an oral antiallergic compound but there is no direct evidence of its anti-inflammatory actions in bronchial asthma." | 5.08 | The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. ( Hoshino, M; Nakamura, Y, 1997) |
| "The study was carried out to investigate the effect of azelastine on the Substance P (SP) concentration in bronchoalveolar (BAL) and nasal (NAL) lavage obtained from atopic grass pollen asthmatics and non-atopic healthy subjects." | 5.07 | Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. ( Baumgarten, C; Furkert, J; Kunkel, G; Laake, E; Müller, S; Nieber, K; Rathsack, R, 1993) |
| "Azelastine significantly inhibited the development of the early asthmatic response." | 5.07 | The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma. ( Holgate, ST; Ollier, S; Twentyman, OP, 1993) |
| "Efficacy and tolerance of azelastine (A 5610; CAS 58581-89-8), a new antiallergic compound with a unique structure, were investigated over up to one year of treatment in 225 male and female out-patients (age mean +/- s = 48 +/- 13 years) suffering from chronified intrinsic asthma." | 5.06 | Long-term multicentric study with azelastine in patients with intrinsic asthma. ( Nowak, H; Ulbrich, E, 1990) |
| "4 mg azelastine administered orally on airway responsiveness, skin prick testing, daily peak expiratory flow rates and symptoms of asthma was compared with placebo in a 7 week double-blind, parallel group study of 24 patients with extrinsic asthma." | 5.06 | A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. ( Aurich, R; Davies, RJ; Gould, CA; Ollier, S, 1988) |
| "Azelastine is a new oral antiasthma agent with bronchodilating and antiallergic properties." | 5.06 | Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time. ( Bucholtz, GA; Kemp, JP; Koepke, JW; Repsher, LH; Spector, SL; Storms, WW; Tinkelman, DG; Van As, A, 1990) |
| "4 mg of azelastine administered orally on immediate allergen-induced airflow obstruction was studied in 20 young patients with asthma." | 5.06 | The effect of single and multiple dose therapy with azelastine on the immediate asthmatic response to allergen provocation testing. ( Davies, RJ; Gould, CA; Ollier, S, 1986) |
| "The effects of the new anti-allergic drug, azelastine, on allergen- and exercise-induced asthma were studied." | 5.05 | Effects of azelastine on allergen- and exercise-induced asthma. ( Fukuda, T; Makino, S; Motojima, S; Ohashi, Y; Otsuka, T, 1985) |
| "Since tranilast, the first inhibitor of chemical mediator (ICMR), had been assessed to be as effective as disodium cromogycate in asthma, several orally active ICMRs, which have no antihistamine or bronchodilator effect, have been developed and prescribed for asthma control in Japan." | 4.79 | [Inhibitor of chemical mediator release]. ( Fujimura, M, 1996) |
| "Because the older antihistamines possessed relatively weak antihistaminic action, as well as sedative and anticholinergic effects, they could not be administered in doses high enough to confer relief to atopic patients with asthma." | 4.78 | Antihistamines in the treatment of clinical asthma. ( Rafferty, P, 1990) |
| "Azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-p hthalazinone hydrochloride), a novel long-acting antiasthmatic/antiallergic drug has been demonstrated to be effective in the treatment both of asthma and of allergic rhinitis." | 4.78 | Azelastine: a multifaceted drug for asthma therapy. ( Achterrath-Tuckermann, U; Minker, E; Paegelow, I; Schmidt, J; Szelenyi, I; Werner, H, 1991) |
| "Our results suggest that antihistamine agents may be effective against alcohol-induced asthma by both blocking H1 receptors and inhibiting histamine release." | 3.70 | Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma. ( Asai, S; Kohno, S; Matsuse, H; Mitsuta, K; Obase, Y; Shimoda, T; Takao, A, 1999) |
| "We investigated the inhibitory effect of azelastine hydrochloride (azelastine), an anti-asthmatic drug, on platelet-activating factor (PAF)-like activity in eosinophils obtained from asthmatic and non-asthmatic patients." | 3.69 | Azelastine hydrochloride inhibits platelet activating factor-like activity in human eosinophils. ( Fukumura, M; Shindo, K, 1996) |
| "A prospective study was designed in asthmatic children treated with azelastine hydrochloride." | 3.69 | Urinary N-methylhistamine in asthmatic children receiving azelastine hydrochloride. ( Iwashita, M; Kamuro, K; Kumamoto, T; Miyata, K; Shimago, A; Takei, S, 1997) |
| "The effect of azelastine hydrochloride (azelastine) on synthesis and release of platelet activating factor (PAF) in alveolar macrophages obtained from asthmatic and non-asthmatic subjects was examined." | 3.69 | Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages. ( Fukumura, M; Hirai, Y; Machida, M; Shindo, K, 1997) |
| "Effect of azelastine hydrochloride (azelastine) on release and production of platelet-activating factor (PAF) in neutrophils obtained from asthmatic and non-asthmatic patients was investigated." | 3.69 | Effect of azelastine hydrochloride on release and production of platelet activating factor in human neutrophils. ( Fukumura, M; Hirai, Y; Koide, K; Shindo, K, 1997) |
| "The correlation between the antiasthma activity of azelastine and the concentrations of azelastine and its major metabolite, desmethylazelastine, in the blood and lung were investigated in guinea pigs." | 3.68 | Pharmacodynamic and pharmacokinetic studies with azelastine in the guinea pig: evidence for preferential distribution into the lung. ( Adusumalli, VE; Chand, N; Diamantis, W; Kucharczyk, N; Langevin, CN; Nolan, K; Pivonka, J; Sofia, RD; Wichmann, JK; Wong, KK, 1993) |
| "We examined the effects of a new antiasthmatic drug, azelastine, on the electromechanical responses of airway smooth muscle to histamine, acetylcholine (ACh), and tetraethylammonium (TEA)." | 3.67 | Azelastine inhibits agonist-induced electromechanical activity in canine tracheal muscle. ( Lee, HK; Sperelakis, N, 1989) |
| "We have investigated the effect of azelastine on bronchial responsiveness in 25 asthmatics, using methacholine inhalation challenge, (Astograph)." | 3.67 | [Effect of azelastine on bronchial hyperresponsiveness]. ( Ikuta, N; Ishiguro, H; Iwata, M; Matsuno, T; Miyatake, H; Naito, Y; Nishiura, T; Tano, M; Tsuji, K, 1989) |
| "This study was designed to clarify whether azelastine, an antiasthmatic drug, could favorably alter bronchial responsiveness in patients with bronchial asthma." | 3.67 | Effect of azelastine, an antiasthmatic drug, on bronchial responsiveness in patients with bronchial asthma. ( Iwata, M; Satake, T; Sugiyama, S; Taki, F; Tano, M, 1989) |
| "The influence of aerosolized azelastine on acute lung anaphylaxis in actively sensitized guinea pigs (experimental asthma model) was studied." | 3.67 | Inhibition of acute lung anaphylaxis by aerosolized azelastine in guinea pigs sensitized by three different procedures. ( Chand, N; Diamantis, W; Nolan, K; Sofia, RD, 1987) |
| "Treatment with azelastine (4 mg/os once daily) inhibited immediate reactions to allergens by 65% (range 55-74) and to histamine by 68% (range 47-82)." | 2.69 | Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. ( Bähre, M; De Weck, AL; Derer, T, 2000) |
| "In 12 patients with bronchial asthma we performed histamine bronchial challenges before and four hours after ingestion of placebo, 2." | 2.66 | The inhibitory effect of azelastine and ketotifen on histamine-induced bronchoconstriction in asthmatic patients. ( Magnussen, H, 1987) |
| "Azelastine did not inhibit the effect of inhaled LTC4; the geometric mean PD20FEV1 LTC4 (nmol) after a single dose and 14 days' treatment was 0." | 2.66 | Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma. ( Albazzaz, MK; Patel, KR, 1988) |
| "Theophylline was stopped 24 hours and other bronchodilators at least 8 hours before the study day." | 2.66 | A dose-response study of the bronchodilator action of azelastine in asthma. ( Bucholtz, GA; Kemp, JP; Meltzer, EO; Middleton, E; Newton, JJ; Orgel, HA; Perhach, JL; Spector, SL; Welch, MJ, 1987) |
| " Despite azelastine and desmethyl azelastine blood levels that were proportionate to the dosage range, the bronchodilator effect as measured by FEV1 and forced expiratory flow rate between 25% and 75% of FVC was proportionately greater with 4 mg of azelastine during the 8-hour study period than the anticipated bronchodilator response with the 8 and 16 mg doses." | 2.66 | Pharmacodynamic evaluation of azelastine in subjects with asthma. ( Katz, RM; Perhach, JL; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1987) |
| "Rhinitis is a common condition that affects a significant proportion of the general population, as well as a high proportion of athletes." | 2.43 | Nasal obstruction, the airway, and the athlete. ( Craig, TJ; Davies, MJ; Fisher, LH, 2005) |
| "Nonallergic rhinitis is a common disease that probably affects as many as 17 million Americans." | 2.41 | Update on nonallergic rhinitis. ( Lieberman, P; Settipane, RA, 2001) |
| " Results demonstrate improved activity of antihistamines by 2 phytochemicals, suggesting dosing strategies for animal trials of ASX- or GB-augmented formulations for seasonal allergic rhinitis and asthma." | 1.38 | In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012) |
| "Azelastine is an oral antiallergic drug." | 1.30 | [The effect of azelastine on bronchial mucosa in bronchial asthma--suppression of cytokine mRNA]. ( Shimojo, J, 1998) |
| "We treated bronchial asthma patients with anti-allergic agents for more than three months, and examined their effects on the airway hyperreactivity in 15 cases; five were short cases (disease duration was less than one year from the onset) and 10 were long cases (disease duration was more than one year)." | 1.28 | [Improvement of airway hyperreactivity in bronchial asthma patients with short disease duration treated with anti-allergic agents]. ( Hoshino, K; Kawasaki, A; Mizushima, Y; Yano, S, 1989) |
| "Azelastine has previously been demonstrated to inhibit histamine release, to antagonize histamine-mediated responses, and to be a bronchodilator." | 1.28 | The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. ( Casale, TB, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (33.78) | 18.7374 |
| 1990's | 37 (50.00) | 18.2507 |
| 2000's | 6 (8.11) | 29.6817 |
| 2010's | 5 (6.76) | 24.3611 |
| 2020's | 1 (1.35) | 2.80 |
| Authors | Studies |
|---|---|
| Paris, D | 1 |
| Cottin, M | 1 |
| Demonchaux, P | 1 |
| Augert, G | 1 |
| Dupassieux, P | 1 |
| Lenoir, P | 1 |
| Peck, MJ | 1 |
| Jasserand, D | 1 |
| Esmaeilzadeh, H | 1 |
| Far, NM | 1 |
| Nabavizadeh, SH | 1 |
| Babaeian, M | 1 |
| Hadipour, M | 1 |
| Alyasin, S | 1 |
| Zappia, CD | 1 |
| Soto, A | 1 |
| Granja-Galeano, G | 1 |
| Fenoy, I | 1 |
| Fernandez, N | 1 |
| Davio, CA | 1 |
| Shayo, C | 1 |
| Fitzsimons, CP | 1 |
| Goldman, A | 1 |
| Monczor, F | 1 |
| Chu, JT | 1 |
| Mösges, R | 1 |
| May, U | 1 |
| Fujimura, M | 2 |
| Mahmoud, FF | 1 |
| Haines, D | 1 |
| Al-Awadhi, R | 1 |
| Arifhodzic, N | 1 |
| Abal, A | 1 |
| Azeamouzi, C | 1 |
| Al-Sharah, S | 1 |
| Tosaki, A | 1 |
| Magnan, A | 1 |
| Fisher, LH | 1 |
| Davies, MJ | 1 |
| Craig, TJ | 1 |
| Richter, K | 1 |
| Grönke, L | 1 |
| Janicki, S | 1 |
| Maus, J | 1 |
| Jörres, RA | 1 |
| Magnussen, H | 3 |
| Motojima, S | 2 |
| Fukuda, T | 2 |
| Makino, S | 3 |
| Chervinsky, P | 1 |
| Grossman, J | 2 |
| Freitag, JJ | 1 |
| Konno, S | 1 |
| Asano, K | 1 |
| Gonokami, Y | 1 |
| Kurokawa, M | 1 |
| Kawazu, K | 1 |
| Okamoto, K | 1 |
| Adachi, M | 1 |
| Shindo, K | 4 |
| Nieber, K | 1 |
| Baumgarten, C | 1 |
| Rathsack, R | 1 |
| Furkert, J | 1 |
| Laake, E | 1 |
| Müller, S | 1 |
| Kunkel, G | 1 |
| Chand, N | 4 |
| Achterrath-Tuckermann, U | 3 |
| Szelenyi, I | 3 |
| Sofia, RD | 4 |
| Diamantis, W | 3 |
| Nolan, K | 3 |
| Pillar, J | 1 |
| Adusumalli, VE | 1 |
| Wichmann, JK | 1 |
| Pivonka, J | 1 |
| Langevin, CN | 1 |
| Wong, KK | 1 |
| Kucharczyk, N | 1 |
| Twentyman, OP | 1 |
| Ollier, S | 4 |
| Holgate, ST | 3 |
| Kanazawa, H | 1 |
| Kurihara, N | 1 |
| Hirata, K | 1 |
| Terakawa, K | 1 |
| Takeda, T | 1 |
| Nakagawa, N | 1 |
| Obata, T | 1 |
| Kobayashi, T | 1 |
| Okada, Y | 1 |
| Nambu, F | 1 |
| Terawaki, T | 1 |
| Furuya, T | 1 |
| Muryobayashi, K | 1 |
| Sawada, M | 1 |
| Aishita, H | 1 |
| Busse, WW | 1 |
| Middleton, E | 2 |
| Storms, W | 1 |
| Dockhorn, RJ | 1 |
| Chu, TJ | 1 |
| Weiler, JM | 1 |
| Bronsky, EA | 1 |
| Mansfield, LE | 1 |
| Bell, TD | 1 |
| Hemsworth, GR | 1 |
| Perhach, JL | 3 |
| D'Eletto, TA | 1 |
| Dam, A | 1 |
| Shioya, T | 2 |
| Ito, N | 2 |
| Sasaki, M | 1 |
| Kagaya, M | 2 |
| Sano, M | 2 |
| Shindo, T | 2 |
| Kashima, M | 1 |
| Miura, M | 2 |
| Fukumura, M | 3 |
| Takei, S | 1 |
| Shimago, A | 1 |
| Iwashita, M | 1 |
| Kumamoto, T | 1 |
| Kamuro, K | 1 |
| Miyata, K | 1 |
| Hirai, Y | 2 |
| Koide, K | 1 |
| Watanabe, H | 1 |
| Imai, M | 1 |
| Ling, M | 1 |
| Sugihara, N | 1 |
| Ohtami, S | 1 |
| Hayakawa, M | 1 |
| Miura, H | 1 |
| Kawai, S | 1 |
| Kobayashi, H | 1 |
| Hoshino, M | 1 |
| Nakamura, Y | 1 |
| Machida, M | 1 |
| Watanabe, A | 1 |
| Miura, S | 1 |
| Kimura, K | 1 |
| Shimojo, J | 1 |
| Takao, A | 1 |
| Shimoda, T | 1 |
| Matsuse, H | 1 |
| Mitsuta, K | 1 |
| Obase, Y | 1 |
| Asai, S | 1 |
| Kohno, S | 1 |
| De Weck, AL | 1 |
| Derer, T | 1 |
| Bähre, M | 1 |
| Settipane, RA | 1 |
| Lieberman, P | 1 |
| Balzano, G | 1 |
| Gallo, C | 1 |
| Masi, C | 1 |
| Cocco, G | 1 |
| Ferranti, P | 1 |
| Melillo, E | 1 |
| Seccia, G | 1 |
| Yano, S | 2 |
| Renesto, P | 1 |
| Balloy, V | 1 |
| Vargaftig, BB | 1 |
| Chignard, M | 1 |
| Kato, M | 1 |
| Morikawa, A | 1 |
| Kimura, H | 1 |
| Shimizu, T | 1 |
| Nakano, M | 1 |
| Kuroume, T | 1 |
| Schmidt, J | 1 |
| Minker, E | 1 |
| Paegelow, I | 1 |
| Werner, H | 1 |
| Nakagawa, T | 1 |
| Yamada, G | 1 |
| Rafferty, P | 3 |
| Frick, OL | 1 |
| Ulbrich, E | 1 |
| Nowak, H | 1 |
| Tinkelman, DG | 1 |
| Bucholtz, GA | 2 |
| Kemp, JP | 2 |
| Koepke, JW | 1 |
| Repsher, LH | 1 |
| Spector, SL | 3 |
| Storms, WW | 1 |
| Van As, A | 1 |
| Todoroki, I | 1 |
| Yoshizawa, I | 1 |
| Kawano, Y | 1 |
| Noma, T | 1 |
| Nakamura, S | 1 |
| Baba, M | 1 |
| Tomioka, S | 1 |
| Kuroiwa, H | 1 |
| Hoshino, K | 1 |
| Kawasaki, A | 1 |
| Mizushima, Y | 1 |
| Koya, N | 1 |
| Moroi, T | 1 |
| Hara, M | 1 |
| Suzuki, S | 1 |
| Tateno, A | 1 |
| Nagata, K | 1 |
| Casale, TB | 1 |
| Kikawa, Y | 1 |
| Nakai, A | 1 |
| Shigematsu, Y | 1 |
| Sudo, M | 1 |
| Suehiro, Y | 1 |
| Hirao, M | 1 |
| Ohtsuka, A | 1 |
| Yoshizawa, T | 1 |
| Kikuchi, H | 1 |
| Ohkuma, A | 1 |
| Horie, T | 1 |
| Okayasu, M | 1 |
| Lee, HK | 1 |
| Sperelakis, N | 1 |
| Ng, WH | 1 |
| Phillips, G | 1 |
| Clough, J | 1 |
| Church, MK | 1 |
| Aurich, R | 3 |
| Iwata, M | 2 |
| Nishiura, T | 1 |
| Ishiguro, H | 1 |
| Ikuta, N | 1 |
| Tano, M | 2 |
| Tsuji, K | 1 |
| Matsuno, T | 1 |
| Naito, Y | 1 |
| Miyatake, H | 1 |
| Sugiyama, S | 1 |
| Taki, F | 1 |
| Satake, T | 1 |
| Reuss, G | 1 |
| Jörres, R | 1 |
| Albazzaz, MK | 1 |
| Patel, KR | 1 |
| Gould, CA | 2 |
| Davies, RJ | 2 |
| Subissi, A | 1 |
| Del Monte, M | 1 |
| Criscuoli, M | 1 |
| Asamoto, H | 1 |
| Kokura, M | 1 |
| Kawakami, A | 1 |
| Sasaki, Y | 1 |
| Fujii, H | 1 |
| Sawano, T | 1 |
| Iso, S | 1 |
| Ooishi, T | 1 |
| Horiuchi, Y | 1 |
| Ohara, N | 1 |
| Meltzer, EO | 1 |
| Orgel, HA | 1 |
| Welch, MJ | 1 |
| Newton, JJ | 1 |
| Rohr, AS | 1 |
| Rachelefsky, GS | 1 |
| Katz, RM | 1 |
| Siegel, SC | 1 |
| Ohashi, Y | 1 |
| Otsuka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of the Nose for Physical Capacity[NCT04712799] | Phase 4 | 67 participants (Anticipated) | Interventional | 2021-01-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for azelastine and Asthma
| Article | Year |
|---|---|
[Causes of prolonged and chronic cough].
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Chronic Disease; Clenbuterol; Cough; Dr | 2008 |
Nasal obstruction, the airway, and the athlete.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Nasal Obstruction; Phthalazines; Respiratory System | 2005 |
[Inhibitor of chemical mediator release].
Topics: Asthma; Clinical Trials as Topic; Depression, Chemical; Double-Blind Method; Histamine H1 Antagonist | 1996 |
Update on nonallergic rhinitis.
Topics: Adrenal Cortex Hormones; Adult; Age of Onset; Air Pollution; Anti-Inflammatory Agents, Non-Steroidal | 2001 |
Azelastine: a multifaceted drug for asthma therapy.
Topics: Animals; Asthma; Free Radicals; Histamine H1 Antagonists; Humans; Interleukin-1; Mucociliary Clearan | 1991 |
Antihistamines in the treatment of clinical asthma.
Topics: Animals; Asthma; Benzhydryl Compounds; Cetirizine; Dose-Response Relationship, Drug; Forced Expirato | 1990 |
24 trials available for azelastine and Asthma
| Article | Year |
|---|---|
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial.
Topics: Acetates; Administration, Intranasal; Adolescent; Adrenal Cortex Hormones; Adult; Asthma; Budesonide | 2022 |
Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma.
Topics: Acetates; Adult; Anti-Allergic Agents; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Cro | 2008 |
Duration of action of a single dose of azelastine in patients with chronic asthma.
Topics: Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Forced E | 1995 |
Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma.
Topics: Adolescent; Adult; Asthma; Bronchoalveolar Lavage Fluid; Exudates and Transudates; Female; Histamine | 1993 |
The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma.
Topics: Adult; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoconstriction; Double-B | 1993 |
Corticosteroid-sparing effect of azelastine in the management of bronchial asthma.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Age | 1996 |
An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group.
Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Chronic | 1996 |
Cough threshold for capsaicin increases by azelastine in patients with cough-variant asthma.
Topics: Adult; Aged; Asthma; Bronchodilator Agents; Capsaicin; Cough; Dose-Response Relationship, Drug; Fema | 1996 |
The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma.
Topics: Adolescent; Adult; Antigens, CD; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents | 1997 |
Antitussive effect of azelastine hydrochloride in patients with bronchial asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Antitussive Agents; Asthma; Bronchial Hyperreactivit | 1998 |
Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography.
Topics: Adult; Allergens; Alternaria; Anti-Allergic Agents; Asthma; Cross-Over Studies; Dermatitis, Atopic; | 2000 |
Effect of azelastine on the seasonal increase in non-specific bronchial responsiveness to methacholine in pollen allergic patients. A randomized, double-blind placebo-controlled, crossover study.
Topics: Administration, Oral; Adolescent; Adult; Allergens; Asthma; Bronchial Hyperreactivity; Double-Blind | 1992 |
Long-term multicentric study with azelastine in patients with intrinsic asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Airway Resistance; Asthma; Body Weight; Bronchodilator A | 1990 |
Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time.
Topics: Adolescent; Adult; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Double-Blind Meth | 1990 |
The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma.
Topics: Adult; Allergens; Asthma; Bronchi; Female; Forced Expiratory Volume; Histamine; Histamine H1 Antagon | 1989 |
The inhibitory effect of azelastine hydrochloride on histamine- and allergen-induced bronchoconstriction in atopic asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Asthma; Bronchi; Double-Blind Method; Force | 1989 |
The inhibitory effect of azelastine and ketotifen on histamine-induced bronchoconstriction in asthmatic patients.
Topics: Adult; Asthma; Bronchial Provocation Tests; Double-Blind Method; Female; Histamine; Histamine H1 Ant | 1987 |
The effect of azelastine on exercise-induced asthma.
Topics: Adult; Asthma; Asthma, Exercise-Induced; Cold Temperature; Double-Blind Method; Exercise Test; Femal | 1988 |
Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma.
Topics: Adult; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Forced Expiratory Volume; Hist | 1988 |
A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Method; Female; Histamine H1 Ant | 1988 |
A dose-response study of the bronchodilator action of azelastine in asthma.
Topics: Adolescent; Adult; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Dose-Response Rel | 1987 |
Pharmacodynamic evaluation of azelastine in subjects with asthma.
Topics: Adolescent; Adult; Asthma; Clinical Trials as Topic; Forced Expiratory Volume; Humans; Middle Aged; | 1987 |
The effect of single and multiple dose therapy with azelastine on the immediate asthmatic response to allergen provocation testing.
Topics: Administration, Oral; Adult; Airway Resistance; Allergens; Asthma; Bronchial Provocation Tests; Dose | 1986 |
Effects of azelastine on allergen- and exercise-induced asthma.
Topics: Adolescent; Adult; Allergens; Asthma; Asthma, Exercise-Induced; Bronchial Provocation Tests; Clinica | 1985 |
44 other studies available for azelastine and Asthma
| Article | Year |
|---|---|
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
Topics: Animals; Asthma; Female; Guinea Pigs; Histamine Antagonists; In Vitro Techniques; Lipoxygenase Inhib | 1995 |
Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model.
Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Dexamethasone; Disease Models, A | 2019 |
Histamine H1 receptor gene polymorphism acts as a biological indicator of the prediction of therapeutic efficacy in patients with allergic rhinitis in the Chinese Han population.
Topics: Administration, Oral; Adolescent; Adult; Asthma; Child; China; Environmental Biomarkers; Eosinophil | 2019 |
All of ARIA in one puff?
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Asthma; Clinical Trials as Topic; | 2014 |
[Socio-economic impact of allergic rhinitis and perspectives of appropriate therapy].
Topics: Absenteeism; Administration, Intranasal; Adolescent; Adult; Androstadienes; Asthma; Child; Child, Pr | 2014 |
In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin.
Topics: Adult; Anti-Allergic Agents; Antioxidants; Asthma; Biomarkers; Case-Control Studies; Cells, Cultured | 2012 |
[Respiratory allergies in the child and the adult].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag | 2004 |
[Comparison of suppressive effects of inhibitor of IgE mediated chemical mediator release and H1-blocker on exercise induced asthma (author's transl)].
Topics: Adult; Asthma; Asthma, Exercise-Induced; Diphenhydramine; Female; Heart Rate; Histamine H1 Antagonis | 1982 |
Effect of azelastine on endotoxin-induced airway hyperresponsiveness in mice.
Topics: Administration, Inhalation; Animals; Asthma; Bronchodilator Agents; Disease Models, Animal; Interleu | 1995 |
Inhibitory effect of azelastine on platelet activating factor-like activity in eosinophils in asthmatic patients.
Topics: Asthma; Eosinophils; Humans; Phthalazines; Platelet Activating Factor; Platelet Aggregation Inhibito | 1995 |
Synergistic protective effects with azelastine and salbutamol in a guinea pig asthma model.
Topics: Administration, Oral; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; | 1995 |
Azelastine inhibits acute allergic dyspnea in a conscious guinea pig asthma model.
Topics: Aerosols; Allergens; Animals; Asthma; Bronchodilator Agents; Dyspnea; Guinea Pigs; Male; Ovalbumin; | 1994 |
Pharmacodynamic and pharmacokinetic studies with azelastine in the guinea pig: evidence for preferential distribution into the lung.
Topics: Animals; Asthma; Guinea Pigs; Histamine H1 Antagonists; Hypersensitivity, Immediate; Lung; Phthalazi | 1993 |
Hyporesponsiveness to inhibitory agents of alveolar macrophages and polymorphonuclear leukocytes primed by platelet activating factor.
Topics: Adult; Aged; Asthma; Bronchial Hyperreactivity; Cells, Cultured; Dexamethasone; Female; Humans; Leuk | 1993 |
Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma.
Topics: Acetylcholine; Acute-Phase Reaction; Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchoconstrict | 1993 |
Azelastine hydrochloride inhibits platelet activating factor-like activity in human eosinophils.
Topics: Animals; Asthma; Dose-Response Relationship, Drug; Eosinophils; Guinea Pigs; Histamine H1 Antagonist | 1996 |
Urinary N-methylhistamine in asthmatic children receiving azelastine hydrochloride.
Topics: Anti-Allergic Agents; Asthma; Child; Child, Preschool; Circadian Rhythm; Dose-Response Relationship, | 1997 |
Effect of azelastine hydrochloride on release and production of platelet activating factor in human neutrophils.
Topics: Asthma; Biological Assay; Dose-Response Relationship, Drug; Humans; N-Formylmethionine Leucyl-Phenyl | 1997 |
[Epileptic seizure most probably caused by azelastine treatment in a patient with bronchial asthma and genuine epilepsy].
Topics: Adult; Asthma; Bronchodilator Agents; Epilepsy; Female; Histamine H1 Antagonists; Humans; Phthalazin | 1997 |
Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages.
Topics: Adult; Asthma; Dose-Response Relationship, Drug; Humans; Macrophages, Alveolar; Male; Middle Aged; P | 1997 |
[The effect of azelastine on bronchial mucosa in bronchial asthma--suppression of cytokine mRNA].
Topics: Adolescent; Adult; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchi; C | 1998 |
Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma.
Topics: Acetaldehyde; Adult; Aged; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Ethanol; Female | 1999 |
[Drug therapy of asthma by antiallergic agents].
Topics: Asthma; Cromolyn Sodium; Histamine Antagonists; Humans; Ketotifen; ortho-Aminobenzoates; Phthalazine | 1992 |
Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Glucuronidase; Humans; In Vitro Techniques; L-Lacta | 1991 |
Effects of antiasthma drugs on superoxide anion generation from human polymorphonuclear leukocytes or hypoxanthine-xanthine oxidase system.
Topics: Adolescent; Asthma; Bronchodilator Agents; Child; Female; Free Radical Scavengers; Humans; Isoproter | 1991 |
[Chemical mediators and anti-mediator drugs].
Topics: Asthma; Chemotactic Factors, Eosinophil; Cromolyn Sodium; Cytokines; Depression, Chemical; Histamine | 1991 |
[Clinical application of enzyme inhibitor in bronchial asthma and respiratory tract infection].
Topics: Animals; Annexins; Asthma; Calcium-Binding Proteins; Cromolyn Sodium; Humans; Lipoxygenase Inhibitor | 1991 |
[Delayed reaction in asthma].
Topics: Adrenal Cortex Hormones; Animals; Asthma; Dogs; Eosinophils; Humans; Hypersensitivity, Delayed; Immu | 1990 |
[Suppressive effect of azelastine on the induction of Df antigen specific IL-2 responsiveness in lymphocytes from patients with bronchial asthma].
Topics: Animals; Antigens; Asthma; Child, Preschool; Humans; Interleukin-2; Lymphocyte Activation; Lymphocyt | 1990 |
[Investigation on the long-term prognosis of occupational asthma].
Topics: Adult; Aged; Asthma; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Middle Aged; Occupat | 1990 |
[Progress of therapeutic agents for asthma--2. Prophylactic anti-asthmatic agents].
Topics: Administration, Inhalation; Administration, Oral; Animals; Asthma; Child, Preschool; Cromolyn Sodium | 1987 |
[Therapeutic aspects of intractable asthma].
Topics: Adult; Aged; Asthma; Cromolyn Sodium; Female; Humans; Ketotifen; Male; Middle Aged; ortho-Aminobenzo | 1988 |
[Improvement of airway hyperreactivity in bronchial asthma patients with short disease duration treated with anti-allergic agents].
Topics: Adult; Asthma; Bronchi; Cromolyn Sodium; Drug Therapy, Combination; Female; Histamine; Humans; Ketot | 1989 |
[The investigation of asthmatic children by multiple factor analysis. III. The changes in allergic factors selected by multiple factor analysis in 3 anti-allergic during treated groups over one year].
Topics: Adolescent; Asthma; Child; Child, Preschool; Eosinophils; Female; Histamine H1 Antagonists; Humans; | 1989 |
The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites.
Topics: Asthma; Binding, Competitive; Humans; Hypersensitivity; Lung; Phthalazines; Pyridazines; Receptors, | 1989 |
[Development of a system for monitoring the production of leukotriene B4, C4, D4 and E4 in whole blood of pediatric asthmatic patients].
Topics: Adolescent; Age Factors; Asthma; Calcium-Binding Proteins; Child; Chromatography, High Pressure Liqu | 1989 |
[Role of plasma histamine and neutrophil chemotactic factor in exercise-induced asthma].
Topics: Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Chemotactic Factors; Female; Histamine; Histami | 1989 |
Azelastine inhibits agonist-induced electromechanical activity in canine tracheal muscle.
Topics: Acetylcholine; Animals; Asthma; Bronchodilator Agents; Dogs; Histamine; Histamine H1 Antagonists; Is | 1989 |
[Effect of azelastine on bronchial hyperresponsiveness].
Topics: Adult; Aged; Airway Resistance; Asthma; Bronchi; Bronchial Provocation Tests; Female; Histamine H1 A | 1989 |
Effect of azelastine, an antiasthmatic drug, on bronchial responsiveness in patients with bronchial asthma.
Topics: Adult; Aged; Asthma; Bronchial Provocation Tests; Dose-Response Relationship, Drug; Drug Evaluation; | 1989 |
Azelastine inhibits bronchial hyperreactivity to acetylcholine in guinea pigs.
Topics: Acetylcholine; Animals; Antigens; Asthma; Bronchi; Guinea Pigs; Histamine; Histamine H1 Antagonists; | 1988 |
Effects of anti-asthma drugs on PAF-induced death in mice.
Topics: Adrenalectomy; Adrenergic beta-Agonists; Animals; Asthma; Bronchodilator Agents; Colforsin; Dexameth | 1988 |
[Effect of azelastine on theophylline clearance in asthma patients].
Topics: Administration, Oral; Adult; Aged; Asthma; Delayed-Action Preparations; Female; Humans; Male; Metabo | 1988 |
Inhibition of acute lung anaphylaxis by aerosolized azelastine in guinea pigs sensitized by three different procedures.
Topics: Aerosols; Anaphylaxis; Animals; Antigens; Asthma; Disease Models, Animal; Guinea Pigs; Injections, I | 1987 |